{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:54:05Z","timestamp":1793642045720,"version":"4.5.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101165","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:40:30Z","timestamp":1700761230000},"page":"101165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers"],"prefix":"10.1016","volume":"31","author":[{"given":"Xiaobo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Radiloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Tabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101165_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2023.101165_bib2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2023.101165_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtm.2023.101165_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtm.2023.101165_bib7","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jhep.2021.12.015","article-title":"Modern therapeutic approaches to liver-related disorders","volume":"76","author":"Gardin","year":"2022","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2023.101165_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dot.2019.55.5.2958475","article-title":"Patisiran for the treatment of patients with familial amyloid polyneuropathy","volume":"55","author":"Rizk","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtm.2023.101165_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1358\/dot.2021.57.1.3230207","article-title":"Givosiran to treat acute porphyria","volume":"57","author":"Honor","year":"2021","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtm.2023.101165_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtm.2023.101165_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000877","article-title":"Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent","volume":"34","author":"Giordano","year":"2023","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.omtm.2023.101165_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/hep4.1405","article-title":"A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.omtm.2023.101165_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1053\/j.gastro.2013.09.009","article-title":"Mice with human livers","volume":"145","author":"Grompe","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtm.2023.101165_bib14","doi-asserted-by":"crossref","first-page":"e0142145","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.101165_bib15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/biomedicines9111647","article-title":"Estimating drug efficacy with a diet-induced NASH model in chimeric mice with humanized livers","volume":"9","author":"Kisoh","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtm.2023.101165_bib16","doi-asserted-by":"crossref","first-page":"11839","DOI":"10.1073\/pnas.0404474101","article-title":"Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex","volume":"101","author":"Kelly","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.101165_bib17","doi-asserted-by":"crossref","first-page":"eaat0344","DOI":"10.1126\/scitranslmed.aat0344","article-title":"Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis","volume":"10","author":"Zhu","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib18","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.xcrm.2023.101016","article-title":"Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH","volume":"4","author":"Conway","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tcb.2018.03.001","article-title":"Crosstalk between YAP\/TAZ and Notch signaling","volume":"28","author":"Totaro","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtm.2023.101165_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.30802\/AALAS-CM-22-000027","article-title":"Characterization and prevention of hypovitaminosis c in chimeric mice with humanized livers","volume":"72","author":"Touchette","year":"2022","journal-title":"Comp. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib21","doi-asserted-by":"crossref","first-page":"eadc9653","DOI":"10.1126\/scitranslmed.adc9653","article-title":"Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis","volume":"15","author":"Xiao","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2023.101165_bib22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00204-013-1078-5","article-title":"Recent advances in 2D and 3D in\u00a0vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME","volume":"87","author":"Godoy","year":"2013","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.omtm.2023.101165_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtm.2023.101165_bib24","doi-asserted-by":"crossref","first-page":"111321","DOI":"10.1016\/j.celrep.2022.111321","article-title":"Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice","volume":"40","author":"Kabbani","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2023.101165_bib25","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.jhepr.2023.100716","article-title":"Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH","volume":"5","author":"Moore","year":"2023","journal-title":"JHEP. Rep."},{"key":"10.1016\/j.omtm.2023.101165_bib26","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2021.11.031","article-title":"TAZ-Induced Cybb in hepatocytes contributes to early liver tumorigenesis in experimental non-alcoholic steatohepatitis (online)","volume":"76","author":"Wang","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtm.2023.101165_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omtm.2023.101165_bib28","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","article-title":"The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell","volume":"293","author":"Plouffe","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.101165_bib29","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2023.101165_bib30","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1152\/ajpregu.00136.2016","article-title":"Sexually dimorphic myeloid inflammatory and metabolic responses to diet-induced obesity","volume":"311","author":"Griffin","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.omtm.2023.101165_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2023.101165_bib32","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00041.2019","article-title":"Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer","volume":"318","author":"Wei","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.omtm.2023.101165_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:22:44Z","timestamp":1762615364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":33,"alternative-id":["S2329050123002048"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101165","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.27.564478","asserted-by":"object"}]},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101165"}}